Pembrolizumab: given beside what is tested

1,547 studies: usual care or a partner of the new treatment. Page 6 of 16. Open to participants first (520), then studies with results posted, then the rest; newest registration first within each.

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsRecruitingNCT04429542Phase 1 Report a problem
A Study of Sigvotatug Vedotin in Advanced Solid TumorsRecruitingNCT04389632Phase 1 Report a problem
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT04370587Phase 1/2 Report a problem
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast CancerRecruitingNCT04348747Phase 2 Report a problem
Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung AdenocarcinomaRecruitingNCT04339218Phase 3 Report a problem
Anlotinib Plus Immune Checkpoint Inhibitors for Lung CancerRecruitingNCT04322617Phase 2/3 Report a problem
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid MalignanciesRecruitingNCT04282044Phase 1 Report a problem
Sacituzumab Govitecan In TNBCRecruitingNCT04230109Phase 2 Report a problem
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsRecruitingNCT04219254Phase 1/2 Report a problem
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)RecruitingNCT04198766Phase 1/2 Report a problem
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)RecruitingNCT04165070Phase 1/2 Report a problem
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor MalignanciesRecruitingNCT04114136Phase 2 Report a problem
Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan StudyEnrolling by invitationNCT03951142Phase 2 Report a problem
Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2 Report a problem
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and LymphomaRecruitingNCT03829254Phase 1/2 Report a problem
PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal CancerRecruitingNCT03638297Phase 2 Report a problem
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaRecruitingNCT03556228Phase 1/2 Report a problem
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsRecruitingNCT03526835Phase 1/2 Report a problem
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerRecruitingNCT03412877Phase 2 Report a problem
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.RecruitingNCT03219450Phase 1 Report a problem
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)TerminatedNCT06984328Phase 2Results posted Report a problem
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination TherapyTerminatedNCT06391775Phase 1/2Results posted Report a problem
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell CarcinomaTerminatedNCT06046482Phase 2Results posted Report a problem
Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal CancerActive, not recruitingNCT05996523Phase 2Results posted Report a problem
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor MalignanciesTerminatedNCT05846659Phase 2Results posted Report a problem
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCCTerminatedNCT05846646Phase 2Results posted Report a problem
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCCTerminatedNCT05814666Phase 2Results posted Report a problem
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 InhibitorsTerminatedNCT05764395Phase 2Results posted Report a problem
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursTerminatedNCT05714553Phase 1/2Results posted Report a problem
Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLCTerminatedNCT05691829Phase 2Results posted Report a problem
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)TerminatedNCT05665595Phase 3Results posted Report a problem
Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung CancerTerminatedNCT05617313Phase 2Results posted Report a problem
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension StudyCompletedNCT05600309Phase 3Results posted Report a problem
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)CompletedNCT05594043Phase 1Results posted Report a problem
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsTerminatedNCT05572684Phase 1/2Results posted Report a problem
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China ExtensionCompletedNCT05523323Phase 3Results posted Report a problem
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)CompletedNCT05508867Phase 2Results posted Report a problem
A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid TumorsTerminatedNCT05491317Phase 1/2Results posted Report a problem
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 GeneTerminatedNCT05469178Phase 1/2Results posted Report a problem
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)CompletedNCT05446870Phase 2Results posted Report a problem
A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in SurgeryTerminatedNCT05446129Phase 1Results posted Report a problem
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)TerminatedNCT05394350Phase 1/2Results posted Report a problem
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic CancersCompletedNCT05383170Phase 1/2Results posted Report a problem
A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)CompletedNCT05323656Phase 2Results posted Report a problem
A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)TerminatedNCT05311176Phase 2Results posted Report a problem
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)TerminatedNCT05267470Phase 1Results posted Report a problem
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid TumorsTerminatedNCT05256381Phase 2Results posted Report a problem
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx CancerActive, not recruitingNCT05232851Phase 1/2Results posted Report a problem
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)TerminatedNCT05226598Phase 3Results posted Report a problem
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)Active, not recruitingNCT05224141Phase 3Results posted Report a problem
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]TerminatedNCT05179603Phase 2Results posted Report a problem
Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal CancerTerminatedNCT05167409Phase 2Results posted Report a problem
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPCTerminatedNCT05166577Phase 1Results posted Report a problem
A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung CancerTerminatedNCT05141357Phase 2Results posted Report a problem
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast CancerCompletedNCT05112536Phase 2Results posted Report a problem
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)CompletedNCT05104567Phase 2Results posted Report a problem
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)TerminatedNCT05092360Phase 3Results posted Report a problem
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid TumorsCompletedNCT05091346Phase 1/2Results posted Report a problem
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBCCompletedNCT05077709Phase 2Results posted Report a problem
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid TumorsTerminatedNCT05070247Phase 1/2Results posted Report a problem
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)CompletedNCT05064059Phase 3Results posted Report a problem
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)TerminatedNCT05061420Phase 2Results posted Report a problem
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial CarcinomaTerminatedNCT05036681Phase 2Results posted Report a problem
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic CancerCompletedNCT05014776Phase 2Results posted Report a problem
9-ING-41 Plus Carboplatin in Salivary Gland CarcinomaActive, not recruitingNCT05010629Phase 2Results posted Report a problem
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)CompletedNCT05007106Phase 2Results posted Report a problem
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)CompletedNCT05005442Phase 2Results posted Report a problem
A Study of SEA-CD40 Given With Other Drugs in CancersCompletedNCT04993677Phase 2Results posted Report a problem
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)TerminatedNCT04969861Phase 2/3Results posted Report a problem
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Phase 3Results posted Report a problem
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.TerminatedNCT04949191Phase 2Results posted Report a problem
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression ParticipantsTerminatedNCT04939701Phase 1/2Results posted Report a problem
Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell CarcinomaTerminatedNCT04936841Phase 2Results posted Report a problem
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial CancerTerminatedNCT04936230Phase 2Results posted Report a problem
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLCTerminatedNCT04925986Phase 2Results posted Report a problem
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)CompletedNCT04924101Phase 2Results posted Report a problem
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)TerminatedNCT04914897Phase 2Results posted Report a problem
A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)CompletedNCT04907851Phase 2Results posted Report a problem
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic MelanomaTerminatedNCT04904185Phase 1Results posted Report a problem
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesTerminatedNCT04902040Phase 1/2Results posted Report a problem
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).CompletedNCT04895722Phase 2Results posted Report a problem
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension StudyCompletedNCT04889118Phase 3Results posted Report a problem
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyCompletedNCT04887870Phase 2/3Results posted Report a problem
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of CancersCompletedNCT04879849Phase 1Results posted Report a problem
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial CarcinomaTerminatedNCT04856189Phase 1/2Results posted Report a problem
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell CarcinomaTerminatedNCT04854499Phase 2Results posted Report a problem
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 AntigenCompletedNCT04837196Phase 1/2Results posted Report a problem
Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver CancerCompletedNCT04828486Phase 2Results posted Report a problem
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.TerminatedNCT04812535Phase 2Results posted Report a problem
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid TumorTerminatedNCT04800627Phase 1/2Results posted Report a problem
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular CarcinomaCompletedNCT04798781Phase 2Results posted Report a problem
Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced MelanomaCompletedNCT04796194Phase 2Results posted Report a problem
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin LymphomaTerminatedNCT04788043Phase 2Results posted Report a problem
FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric CancerCompletedNCT04768686Phase 2Results posted Report a problem
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)CompletedNCT04740307Phase 2Results posted Report a problem
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)TerminatedNCT04738487Phase 3Results posted Report a problem
TAC T-cells for the Treatment of HER2-positive Solid TumorsTerminatedNCT04727151Phase 1/2Results posted Report a problem
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)CompletedNCT04725188Phase 2Results posted Report a problem
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid TumorsTerminatedNCT04717375Phase 1/2Results posted Report a problem
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension StudyCompletedNCT04716933Phase 3Results posted Report a problem

← Pembrolizumab